Shares of Aequus Pharmaceuticals Inc. (CVE:AQS – Get Free Report) hit a new 52-week low on Wednesday . The stock traded as low as C$0.01 and last traded at C$0.01, with a volume of 88000 shares traded. The stock had previously closed at C$0.01.
Aequus Pharmaceuticals Stock Down 50.0 %
The firm has a market cap of C$663,150.00, a P/E ratio of -0.50 and a beta of -0.02. The company has a current ratio of 0.07, a quick ratio of 0.46 and a debt-to-equity ratio of 138.88. The business has a 50-day moving average price of C$0.01 and a 200-day moving average price of C$0.01.
Aequus Pharmaceuticals Company Profile
Aequus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. The company markets ZIMED PF, a preservative-free bimatoprost ophthalmic solution. It also develops a range of prescription-free dry eye products under the OPTASE name; and REV-0100 for the treatment of stargardt disease.
Featured Articles
- Five stocks we like better than Aequus Pharmaceuticals
- Why Invest in High-Yield Dividend Stocks?
- What GTC 2025 Signals for NVIDIA Stock’s Next Big Move
- Diversification Can Smooth Returns And Mitigate Portfolio Risk
- Alphabet’s Officially In A Bear Market—Time To Buy?
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- D-Wave and Quantum Supremacy: Implications For Investors
Receive News & Ratings for Aequus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aequus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
